EVE Health Group (ASX:EVE) completed the acquisition of Nextract after the deal was settled through the issue of 83.3 million fully paid ordinary shares in the firm at a post-consolidation price of AU$0.036 per share, according to a Thursday Australian bourse filing.
It also completed a AU$1 million placement to sophisticated and professional investors, issuing 27.8 million shares at the same price, with the proceeds to fund the integration, initial manufacturing scale-up, and regulatory submissions for Nextract.
It also opened its share purchase plan for existing shareholders to raise up to AU$500,000.
Further, the company appointed Stuart Gunzburg as its Chief Scientific Officer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.